Private Companies
Neil Markey, CEO of Beckley Retreats, Sits in the Investor Hotseat on November 23rd
Beckley Retreats CEO, Neil Markey, joins the Investor Hotseat to field hot questions from the host, Dustin Robinson of Iter Investments. A Captain in the…
Beckley Retreats CEO, Neil Markey, joins the Investor Hotseat to field hot questions from the host, Dustin Robinson of Iter Investments.
A Captain in the US Army Special Operations 2nd Ranger Battalion, Neil was deployed once to Iraq, and twice to Afghanistan. After, as an MBA/MIA master’s student at Columbia University, he suffered from depression and PTSD. This led him to alternative well-being practices and marked the start of a profound healing journey with mindfulness and psychedelics. Prior to Beckley Retreats, Neil worked as the Chief Growth Officer for a $450M private equity portfolio company where he was responsible for all strategy and growth planning. Before that he worked as a consultant at McKinsey & Co, where he co-led the internal mindfulness program.
Will Neil be able to handle the heat in the hotseat?
As always, this will be a live event. You’ll be able to stream it from the Psychedelic Invest website, YouTube, LinkedIn, Facebook, Twitch, and Twitter. If you miss it, though, don’t worry. It will be recorded and available across those channels after the event.
If you’d like to attend the live event, you can set a reminder on Youtube or LinkedIn. Or, you can return to the Hotseat livestream page at the time of the event.
To RSVP to ensure your spot, please fill out the form below.
A Transcription Will Be Available Following the Event
-
Psychedelics1 week ago
Exploring Psilocybin’s Potential in Diabetes Management
-
Psychedelics1 week ago
All About the New Ketamine Trial at the University of Otago
-
Psychedelics1 week ago
Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
-
Law & Regulation1 week ago
Canada’s Optimi Health to ship psilocybin to New Zealand psychedelics research center
-
Law & Regulation1 week ago
Synaptogenix increases psilocybin stake with PsygaBio
-
Psychedelics1 week ago
The EU’s Plan for a €6.5M Study of Psychedelics To Treat Mental Disorders
-
Psychedelics1 week ago
Exploring Psilocybin’s Potential in Diabetes Management
-
Psychedelics1 week ago
The EU’s Plan for a €6.5M Study of Psychedelics To Treat Mental Disorders